Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3475 + mFOLFOX6 in Advanced GI Cancers
NCT02268825Phase 1Terminated
- Sponsor
- University of Utah
- Start
- Jan 2015
- Primary completion
- Jan 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in colorectal cancer (CRC), appendiceal adenocarcinoma, gastroesophageal junction cancer and 2 more, sponsored by University of Utah. Primary endpoint: Safety of combination mFOLFOX and MK-3475. Started Jan 2015; status: terminated.
02
Drugs
03
Conditions
colorectal cancer (CRC)appendiceal adenocarcinomagastroesophageal junction cancerpancreatic cancer (PC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02268825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268825.